8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Dec 15, 2025·SEC
Arcturus Therapeutics Holdings Inc.(ARCT)Earnings, Financials & Key Ratios
ARCT•NASDAQ
$7.60
Price updated Jul 7, 2026
AboutArcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.Show more
- Revenue$67M-51.4%
- EBITDA-$72M+21.9%
- Net Income-$66M+18.7%
- EPS (Diluted)-2.40+20.0%
- Gross Margin95.5%-4.5%
- EBITDA Margin-107.01%-60.7%
- Operating Margin-111.51%-61.3%
- Net Margin-97.86%-67.3%
- ROE-28.92%+7.2%
ARCT Price & Volume
Arcturus Therapeutics Holdings Inc. (ARCT) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependence Strains Arcturus Clinical Revenue Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical Milestone Revenue Volatility
Key Thesis Takeaways
- Arcturus Therapeutics faces a challenging transition from a milestone-dependent licensing model to a sustainable commercial entity, as evidenced by a 97.9% revenue contraction in 2026Q1.
- While the company maintains a sufficient liquidity buffer with $211.4M in cash, the persistent reliance on episodic payments and high R&D spending creates significant earnings volatility.
- Investors should monitor the company's ability to achieve recurring product-based cash flows, as the current reliance on stock-based compensation, averaging over $7M per quarter, continues to obscure the true underlying cash burn.
Verdict Logic
the company's reliance on sporadic milestone payments and a significant accumulated deficit of $541.6M suggest that the current business model lacks the necessary scale to achieve sustained profitability in the near term.
ARCT Growth Metrics
Arcturus Therapeutics Holdings Inc. (ARCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.04%
5 Years47.77%
3 Years-31.13%
TTM-66.45%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-11.86%
Return on Capital
10 Years-34.7%
5 Years-27.09%
3 Years-27.69%
Last Year-29.2%
ARCT Recent Earnings
Arcturus Therapeutics Holdings Inc. (ARCT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.95+7.9%
$1.03
Rev
$2M-67.3%
$6M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$1.03-12.0%
$0.92
Rev
$7M-54.7%
$16M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.49+38.7%
$0.80
Rev
$17M+7.0%
$16M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.34+69.4%
$1.11
Rev
$25M+33.6%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.95vs $1.03+7.9% | $2Mvs $6M-67.3% |
| Q2 2026 | Mar 3, 2026 | $1.03vs $0.92-12.0% | $7Mvs $16M-54.7% |
| Q4 2025 | Nov 10, 2025 | $0.49vs $0.80+38.7% | $17Mvs $16M+7.0% |
| Q3 2025 | Aug 11, 2025 | $0.34vs $1.11+69.4% | $25Mvs $18M+33.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Arcturus Therapeutics Holdings Inc. (ARCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.60 | $216.02M | -3.17 | -51.43% | -97.86% | -28.92% | — | |
| $79.77 | $31.64B | -10.99 | -39.23% | -143.55% | -36.73% | — | |
| $94.29 | $23.84B | -18.30 | 0.2% | -44.95% | -6.72% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — |
Compare ARCT vs Peers
Arcturus Therapeutics Holdings Inc. (ARCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARCT SEC Filings & Documents
Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ARCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARCT Frequently Asked Questions
Arcturus Therapeutics Holdings Inc. (ARCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Arcturus Therapeutics Holdings Inc.'s revenue?
Arcturus Therapeutics Holdings Inc. (ARCT) reported $45.4M in revenue for fiscal year 2025.
How fast is Arcturus Therapeutics Holdings Inc. growing?
Arcturus Therapeutics Holdings Inc. (ARCT) saw revenue decline by 51.4% over the past year.
Is ARCT profitable?
Arcturus Therapeutics Holdings Inc. (ARCT) reported a net loss of $78.7M for fiscal year 2025.
Dividend & Returns
What is ARCT's return on equity?
Arcturus Therapeutics Holdings Inc. (ARCT) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
What is Arcturus Therapeutics Holdings Inc.'s free cash flow?
Arcturus Therapeutics Holdings Inc. (ARCT) had negative free cash flow of $58.9M in fiscal year 2025, likely due to heavy capital investments.